ストックスクリーナーアプリを入手
29.76
4.83%
1.37
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet
Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat
Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan
Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM) - simplywall.st
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing - TradingView
Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC - MarketBeat
(BEAM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Beam Therapeutics (NASDAQ:BEAM) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - webull.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc (BEAM) Stock News Today - TradingKey
First Trust Advisors LP Increases Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $43 to $78 - moomoo.com
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM) - The Globe and Mail
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus - Yahoo Finance
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $51.07, Implies 80% Upside - TradingView
BofA Adjusts Price Target on Beam Therapeutics to $43 From $47 - marketscreener.com
BEAM SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Beam Therapeutics completes dosing in sickle cell trial - Investing.com
Beam Therapeutics completes dosing in sickle cell trial By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary - TradingView
Beam Therapeutics Reports Q2 2026 Results and Clinical Updates for BEAM-302, Risto-cel and BEAM-304 - Quiver Quantitative
Beam Therapeutics (Nasdaq: BEAM) holds $1.2B cash, plans risto-cel BLA - Stock Titan
Beam Therapeutics reports Q2 2026 results: $1.15B cash, $122.7M net loss - TradingView
Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans - Stock Titan
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam expects $1.2B cash plus $200M draw to fund plans into mid-2029 - Stock Titan
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Potential 101.88% Upside in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Valuation With Upside Left (NASDAQ:BEAM) - Seeking Alpha
Dimensional Fund Advisors LP Has $51.33 Million Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Renaissance Technologies LLC Boosts Stake in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. $BEAM Shares Sold by Liontrust Investment Partners LLP - MarketBeat
Beam Therapeutics (BEAM) CMO sells 16,667 shares under 10b5-1 plan - Stock Titan
Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat
Beam Therapeutics (BEAM) insider Amy Simon plans sale of 16,677 common shares - Stock Titan
Beam Therapeutics (BEAM) Revenue BreakdownMain Composition - Moomoo
TradingKey - TradingKey
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BEAM|Beam Therapeutics Inc|Price:25.100|Chg%:-0.810 - TradingKey
Beam Therapeutics Inc (BEAM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):